222 related articles for article (PubMed ID: 25937339)
1. Activity of botulinum neurotoxin type D (strain 1873) in human neurons.
Pellett S; Tepp WH; Scherf JM; Pier CL; Johnson EA
Toxicon; 2015 Jul; 101():63-9. PubMed ID: 25937339
[TBL] [Abstract][Full Text] [Related]
2. Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").
Pellett S; Tepp WH; Lin G; Johnson EA
Toxicon; 2018 Jun; 147():38-46. PubMed ID: 29273248
[TBL] [Abstract][Full Text] [Related]
3. Botulinum Neurotoxins Can Enter Cultured Neurons Independent of Synaptic Vesicle Recycling.
Pellett S; Tepp WH; Scherf JM; Johnson EA
PLoS One; 2015; 10(7):e0133737. PubMed ID: 26207366
[TBL] [Abstract][Full Text] [Related]
4. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems.
Elliott M; Maignel J; Liu SM; Favre-Guilmard C; Mir I; Farrow P; Hornby F; Marlin S; Palan S; Beard M; Krupp J
PLoS One; 2017; 12(10):e0185628. PubMed ID: 28982136
[TBL] [Abstract][Full Text] [Related]
6. The in vitro detection of botulinum neurotoxin-cleaved endogenous VAMP is epitope-dependent.
Gray B; Cadd V; Elliott M; Beard M
Toxicol In Vitro; 2018 Apr; 48():255-261. PubMed ID: 29373835
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a novel botulinum neurotoxin.
Zhang S; Masuyer G; Zhang J; Shen Y; Lundin D; Henriksson L; Miyashita SI; Martínez-Carranza M; Dong M; Stenmark P
Nat Commun; 2017 Aug; 8():14130. PubMed ID: 28770820
[TBL] [Abstract][Full Text] [Related]
8. Production of serotype C specific and serotype C/D generic monoclonal antibodies using recombinant H(C) and H(N) fragments from Clostridium botulinum neurotoxin types C(1) and D.
Curran RM; Fringuelli E; Graham D; Elliott CT
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):1-10. PubMed ID: 19233482
[TBL] [Abstract][Full Text] [Related]
9. Unique biological activity of botulinum D/C mosaic neurotoxin in murine species.
Nakamura K; Kohda T; Shibata Y; Tsukamoto K; Arimitsu H; Hayashi M; Mukamoto M; Sasakawa N; Kozaki S
Infect Immun; 2012 Aug; 80(8):2886-93. PubMed ID: 22665374
[TBL] [Abstract][Full Text] [Related]
10. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
11. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
Adler M; Keller JE; Sheridan RE; Deshpande SS
Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Botulinum Neurotoxin-like Toxin in a Commensal Strain of Enterococcus faecium.
Zhang S; Lebreton F; Mansfield MJ; Miyashita SI; Zhang J; Schwartzman JA; Tao L; Masuyer G; Martínez-Carranza M; Stenmark P; Gilmore MS; Doxey AC; Dong M
Cell Host Microbe; 2018 Feb; 23(2):169-176.e6. PubMed ID: 29396040
[TBL] [Abstract][Full Text] [Related]
13. Botulinum neurotoxin X lacks potency in mice and in human neurons.
Gregg BM; Matsumura T; Wentz TG; Tepp WH; Bradshaw M; Stenmark P; Johnson EA; Fujinaga Y; Pellett S
mBio; 2024 Mar; 15(3):e0310623. PubMed ID: 38347673
[TBL] [Abstract][Full Text] [Related]
14. In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.
Pellett S; Tepp WH; Whitemarsh RC; Bradshaw M; Johnson EA
Toxicon; 2015 Dec; 107(Pt A):37-42. PubMed ID: 26130522
[TBL] [Abstract][Full Text] [Related]
15. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.
Pellett S; Tepp WH; Bradshaw M; Kalb SR; Dykes JK; Lin G; Nawrocki EM; Pier CL; Barr JR; Maslanka SE; Johnson EA
mSphere; 2016; 1(1):. PubMed ID: 27303710
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the functional activity of botulinum neurotoxin subtype B6.
Kohda T; Nakamura K; Hosomi K; Torii Y; Kozaki S; Mukamoto M
Microbiol Immunol; 2017 Nov; 61(11):482-489. PubMed ID: 28898517
[TBL] [Abstract][Full Text] [Related]
17. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW; Chai Q; Christian T; Stevens RC
Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
[TBL] [Abstract][Full Text] [Related]
18. A protein chip membrane-capture assay for botulinum neurotoxin activity.
Marconi S; Ferracci G; Berthomieu M; Kozaki S; Miquelis R; Boucraut J; Seagar M; Lévêque C
Toxicol Appl Pharmacol; 2008 Dec; 233(3):439-46. PubMed ID: 18845174
[TBL] [Abstract][Full Text] [Related]
19. Analysis of gene expression in induced pluripotent stem cell-derived human neurons exposed to botulinum neurotoxin A subtype 1 and a type A atoxic derivative.
Scherf JM; Hu XS; Tepp WH; Ichtchenko K; Johnson EA; Pellett S
PLoS One; 2014; 9(10):e111238. PubMed ID: 25337697
[TBL] [Abstract][Full Text] [Related]
20. Botulinum neurotoxin serotype D attacks neurons via two carbohydrate-binding sites in a ganglioside-dependent manner.
Strotmeier J; Lee K; Völker AK; Mahrhold S; Zong Y; Zeiser J; Zhou J; Pich A; Bigalke H; Binz T; Rummel A; Jin R
Biochem J; 2010 Oct; 431(2):207-16. PubMed ID: 20704566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
